載入...
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatmen...
Na minha lista:
| 發表在: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7257860/ https://ncbi.nlm.nih.gov/pubmed/32523631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920921980 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|